Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms
Tinsay A. Woreta(Johns Hopkins University), Arun J. Sanyal(Virginia Commonwealth University), Manal F. Abdelmalek(Mayo Clinic), Emily Mitchell(Scientific Services), David E. Kleiner(National Institutes of Health), Norah A. Terrault(University of Southern California), Samer Gawrieh(Indiana University School of Medicine), Anna Mae Diehl(Duke Medical Center), Raj Vuppalanchi(University of Pennsylvania), Mariana Lazo(Drexel University), Mark Fishbein(Northwestern University), Rohit Loomba(University of California San Diego), Mark L. Van Natta(Johns Hopkins University), Arthur J. McCullough(Cleveland Clinic), Cynthia Behling(Johns Hopkins University), Jeanne M. Clark(Johns Hopkins University), Paula M. Hertel(Baylor College of Medicine), Brent A. Neuschwander‐Tetri(Saint Louis University), Laura Wilson(Johns Hopkins University), Arunkumar Krishnan(West Virginia University), Naga Chalasani(Indiana University – Purdue University Indianapolis), Kris V. Kowdley(Liver Institute Northwest), Laura Miriel(Johns Hopkins University), Mohammad Shadab Siddiqui(Virginia Commonwealth University), James Tonascia(Johns Hopkins University), Srinivasan Dasarathy(Cleveland Clinic)
Cited by 43
Related Papers
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
|Hepatology|2017|7.2k
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k